Literature DB >> 20082461

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Joseph L Kissil1, Jaishri O Blakeley, Rosalie E Ferner, Susan M Huson, Michel Kalamarides, Victor-Felix Mautner, Frank McCormick, Helen Morrison, Roger Packer, Vijaya Ramesh, Nancy Ratner, Katherine A Rauen, David A Stevenson, Kim Hunter-Schaedle, Kathryn North.   

Abstract

The NF Conference is the largest annual gathering of researchers and clinicians focused on neurofibromatosis and has been convened by the Children's Tumor Foundation for over 20 years. The 2009 NF Conference was held in Portland, Oregon from June 13 to June 16, 2009 and co-chaired by Kathryn North from the University of Sydney and The Children's Hospital at Westmead, Sydney, Australia; and Joseph Kissil from the Wistar Institute, Philadelphia. The Conference included 80 platform presentations in 9 sessions over 4 days; over 100 abstracts presented as posters; and three Keynote presentations. To date, there have been tremendous advances in basic research in the pathogenesis of neurofibromatosis, and more recently in progress toward identifying effective drug therapies and the commencement of neurofibromatosis clinical trials. The NF Conference attendees have significantly increased (doubling from 140 in 2005 to 280 attending in 2009) with a significant increase in attendance of physicians and clinical researchers. Correspondingly the NF Conference scope has expanded to include translational research, clinical trials and clinical management issues while retaining a core of basic research. These themes are reflected in the highlights from the 2009 NF Conference presented here. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20082461      PMCID: PMC2818482          DOI: 10.1002/ajmg.a.33189

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  29 in total

1.  Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

Authors:  Eric O'Neill; Linda Rushworth; Manuela Baccarini; Walter Kolch
Journal:  Science       Date:  2004-12-24       Impact factor: 47.728

2.  The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis.

Authors:  Fisun Hamaratoglu; Maria Willecke; Madhuri Kango-Singh; Riitta Nolo; Eric Hyun; Chunyao Tao; Hamed Jafar-Nejad; Georg Halder
Journal:  Nat Cell Biol       Date:  2005-12-11       Impact factor: 28.824

3.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

4.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

Review 5.  Diagnostic criteria for schwannomatosis.

Authors:  M MacCollin; E A Chiocca; D G Evans; J M Friedman; R Horvitz; D Jaramillo; M Lev; V F Mautner; M Niimura; S R Plotkin; C N Sang; A Stemmer-Rachamimov; E S Roach
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

6.  Germline mutation of INI1/SMARCB1 in familial schwannomatosis.

Authors:  Theo J M Hulsebos; Astrid S Plomp; Ruud A Wolterman; Els C Robanus-Maandag; Frank Baas; Pieter Wesseling
Journal:  Am J Hum Genet       Date:  2007-02-16       Impact factor: 11.025

7.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Authors:  Hilde Brems; Magdalena Chmara; Mourad Sahbatou; Ellen Denayer; Koji Taniguchi; Reiko Kato; Riet Somers; Ludwine Messiaen; Sofie De Schepper; Jean-Pierre Fryns; Jan Cools; Peter Marynen; Gilles Thomas; Akihiko Yoshimura; Eric Legius
Journal:  Nat Genet       Date:  2007-08-19       Impact factor: 38.330

9.  The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.

Authors:  Nancy M Joseph; Jack T Mosher; Johanna Buchstaller; Paige Snider; Paul E McKeever; Megan Lim; Simon J Conway; Luis F Parada; Yuan Zhu; Sean J Morrison
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

10.  Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.

Authors:  Shyra J Miller; Walter J Jessen; Tapan Mehta; Atira Hardiman; Emily Sites; Sergio Kaiser; Anil G Jegga; Hua Li; Meena Upadhyaya; Marco Giovannini; David Muir; Margaret R Wallace; Eva Lopez; Eduard Serra; G Petur Nielsen; Conxi Lazaro; Anat Stemmer-Rachamimov; Grier Page; Bruce J Aronow; Nancy Ratner
Journal:  EMBO Mol Med       Date:  2009-07       Impact factor: 12.137

View more
  9 in total

1.  The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.

Authors:  Rachael E Hornigold; John F Golding; Guy Leschziner; Rupert Obholzer; Michael J Gleeson; Nick Thomas; Daniel Walsh; Shakeel Saeed; Rosalie E Ferner
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

2.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

3.  Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.

Authors:  Laura-Nanna Lohkamp; Patricia Parkin; Allan Puran; Ute Katharina Bartels; Eric Bouffet; Uri Tabori; James Thomas Rutka
Journal:  Front Surg       Date:  2022-05-03

Review 4.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675

5.  EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis.

Authors:  Pingyu Zhang; Jeannine Garnett; Chad J Creighton; Ghadah Abbas Al Sannaa; Davis R Igram; Alexander Lazar; Xiuping Liu; Changgong Liu; Raphael E Pollock
Journal:  J Pathol       Date:  2014-02       Impact factor: 7.996

6.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

Review 7.  NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Authors:  Rebecca Dunbar Schroeder; Laura S Angelo; Razelle Kurzrock
Journal:  Oncotarget       Date:  2014-01-15

8.  Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.

Authors:  P K Manchanda; G N Jones; A A Lee; D R Pringle; M Zhang; L Yu; K M D La Perle; L S Kirschner
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.

Authors:  Hui-Ling Chen; Haeri Seol; Kristy Jean Brown; Heather Gordish-Dressman; Ashley Hill; Vittorio Gallo; Roger Packer; Yetrib Hathout
Journal:  Int J Mol Sci       Date:  2012-07-24       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.